Susquehanna International Group
EDIT icon

Susquehanna International Group’s Editas Medicine EDIT Stock Holding History

Susquehanna International Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$228K Sell
92,500
-17,200
-16% -$36.4K ﹤0.01% 11448
2025
Q4 		$225K Buy
109,700
+46,200
+73% +$133K ﹤0.01% 10615
2025
Q3 		$220K Sell
63,500
-46,100
-42% -$129K ﹤0.01% 10783
2025
Q2 		$241K Buy
109,600
+4,500
+4% +$7.36K ﹤0.01% 10830
2025
Q1 		$122K Buy
105,100
+28,600
+37% +$42.1K ﹤0.01% 11399
2024
Q4 		$97.2K Sell
76,500
-74,600
-49% -$190K ﹤0.01% 11367
2024
Q3 		$515K Buy
151,100
+11,700
+8% +$50.9K ﹤0.01% 8393
2024
Q2 		$651K Sell
139,400
-76,500
-35% -$432K ﹤0.01% 7609
2024
Q1 		$1.6M Buy
215,900
+32,100
+17% +$267K ﹤0.01% 5843
2023
Q4 		$1.86M Buy
183,800
+127,400
+226% +$1.12M ﹤0.01% 5516
2023
Q3 		$440K Buy
56,400
+300
+0.5% +$2.57K ﹤0.01% 8531
2023
Q2 		$462K Sell
56,100
-13,400
-19% -$117K ﹤0.01% 8509
2023
Q1 		$504K Sell
69,500
-115,600
-62% -$1.03M ﹤0.01% 8549
2022
Q4 		$1.64M Sell
185,100
-58,500
-24% -$642K ﹤0.01% 5088
2022
Q3 		$2.98M Buy
243,600
+24,000
+11% +$374K ﹤0.01% 4103
2022
Q2 		$2.6M Sell
219,600
-39,900
-15% -$535K ﹤0.01% 4351
2022
Q1 		$4.94M Sell
259,500
-84,000
-24% -$1.56M ﹤0.01% 3664
2021
Q4 		$9.12M Sell
343,500
-614,500
-64% -$21.2M ﹤0.01% 2861
2021
Q3 		$39.4M Buy
958,000
+524,400
+121% +$28.7M 0.01% 1333
2021
Q2 		$24.6M Buy
433,600
+77,100
+22% +$2.85M ﹤0.01% 1808
2021
Q1 		$15M Buy
356,500
+87,200
+32% +$4.97M ﹤0.01% 2239
2020
Q4 		$18.9M Buy
269,300
+120,100
+80% +$4.93M ﹤0.01% 1805
2020
Q3 		$4.19M Buy
149,200
+58,400
+64% +$1.9M ﹤0.01% 3302
2020
Q2 		$2.69M Sell
90,800
-47,700
-34% -$1.25M ﹤0.01% 3979
2020
Q1 		$2.75M Sell
138,500
-243,600
-64% -$6.14M ﹤0.01% 3435
2019
Q4 		$11.3M Buy
382,100
+43,200
+13% +$1.08M ﹤0.01% 1958
2019
Q3 		$7.71M Sell
338,900
-17,400
-5% -$431K ﹤0.01% 2239
2019
Q2 		$8.81M Sell
356,300
-52,300
-13% -$1.25M ﹤0.01% 2012
2019
Q1 		$9.99M Buy
408,600
+57,500
+16% +$1.3M ﹤0.01% 1751
2018
Q4 		$7.99M Sell
351,100
-88,900
-20% -$2.42M ﹤0.01% 1814
2018
Q3 		$14M Sell
440,000
-7,900
-2% -$255K ﹤0.01% 1622
2018
Q2 		$16M Sell
447,900
-277,400
-38% -$9.82M 0.01% 1486
2018
Q1 		$24M Buy
725,300
+198,400
+38% +$7.07M 0.01% 1085
2017
Q4 		$16.2M Buy
526,900
+224,400
+74% +$5.65M 0.01% 1412
2017
Q3 		$7.26M Buy
302,500
+12,500
+4% +$238K ﹤0.01% 2081
2017
Q2 		$4.87M Buy
290,000
+6,100
+2% +$110K ﹤0.01% 2447
2017
Q1 		$6.34M Buy
+283,900
New +$5.88M ﹤0.01% 2095

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group's EDIT Position: Q1 2026 in Review

Susquehanna International Group reduced its Editas Medicine (EDIT) stake by 90% in Q1 2026, selling an estimated $1.34M and leaving 73,105 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #11800.

Susquehanna International Group first reported a position in EDIT in Q4 2016 and has held it in 37 quarters since. The position peaked at $18.6M in Q2 2021. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Susquehanna International Group held 73,105 shares of Editas Medicine worth $181K as of Q1 2026.
  • Susquehanna International Group sold 631,557 Editas Medicine shares in Q1 2026, an estimated $1.34M.
  • Editas Medicine made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11800 holding.
  • Susquehanna International Group first reported a position in Editas Medicine in Q4 2016 and has held it in 37 quarters since.
  • Susquehanna International Group's Editas Medicine position peaked at $18.6M in Q2 2021.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.